Impact of the Therapeutic Education Program "living with a Chronic Inflammatory Disease Under Biotherapy" on Patient Compliance and Quality of Life

Last updated: March 13, 2025
Sponsor: Groupe Hospitalier de Bretagne Sud
Overall Status: Active - Recruiting

Phase

N/A

Condition

Ulcerative Colitis (Pediatric)

Treatment

questionnaires

Clinical Study ID

NCT06620770
56LORC_2023_IMPEBIO
  • Ages > 18
  • All Genders

Study Summary

Patient therapeutic education programs have been shown to be effective in many specialties, allowing "Improving biological and psychological parameters, allowing patients to improve their health knowledge, therapeutic adherence and sense of personal effectiveness." Several studies have shown that patient knowledge, adherence and satisfaction are better after attending a therapeutic education program.

This multidisciplinary program is presented and offered to all patients with chronic disease treated by subcutaneous biotherapy, followed by dermatologists, rheumatologists and gastroenterologists of the Lorient hospital.

The study aims to demonstrate the benefit of the Patient Therapeutic Education program at GHBS Lorient "living with a chronic inflammatory disease under biotherapy" on treatment adherence, as well as the positive impact on quality of life.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • All major patients followed up on GHBS for chronic inflammatory disease treated withS/C biotherapy.

  • Patients not opposed to their participation in the research.

  • Less than 3 months between inclusion and start of Therapeutic Education Program.

Exclusion

Exclusion Criteria:

  • Subcutaneous injection by another person.

  • Patients with cognitive impairment.

  • Persons of legal age who are the subject of a legal protection (safeguarding ofjustice, curatorship, guardianship), persons deprived of liberty.

  • Pregnant women.

  • Persons not covered by social security.

Study Design

Total Participants: 126
Treatment Group(s): 1
Primary Treatment: questionnaires
Phase:
Study Start date:
February 14, 2025
Estimated Completion Date:
March 31, 2028

Study Description

All patients followed up as part of their chronic disease and treated with subcutaneous biotherapy in the dermatology, rheumatology, hepatotherapygastroenterology, will be offered participation in the therapeutic education program by GHBS specialists. Whether they agree to participate or not, doctors will offer them participation in the IMPEBIO study.

Patients treated with subcutaneous biotherapy who do not wish to participate in the program will be included in the control group.

Patients treated with subcutaneous biotherapy who wish to participate in this program will be included in the intervention group. The therapeutic education program will begin within 3 months of inclusion.

If the patient does not object, the Morisky scale and the SF 12 questionnaire will be given to him. It may be assisted with filling if necessary by a clinical researcher.

Patients will first complete the Morisky test, and the quality of life questionnaire SF 12 at inclusion in the IMPEBIO study (J0), then to M6 (6 months), M12 (12 months) and M18 (18 months).

These questionnaires will then be retrieved, anonymized and sent to the investigation department. The analysis of questionnaires will not lead to changes in patient management.

Estimated time to complete the questionnaires is 10 minutes.

Connect with a study center

  • Groupe Hospitalier de Bretagne Sud

    Lorient, 56100
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.